These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 29262927

  • 1. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H, Li JY, Sun C, Zhou X.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [Abstract] [Full Text] [Related]

  • 2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.
    Cancer; 2019 Feb 01; 125(3):416-423. PubMed ID: 30332496
    [Abstract] [Full Text] [Related]

  • 3. Plasma cell leukemia: from biology to treatment.
    Jelinek T, Kryukov F, Rihova L, Hajek R.
    Eur J Haematol; 2015 Jul 01; 95(1):16-26. PubMed ID: 25778450
    [Abstract] [Full Text] [Related]

  • 4. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P, Simeon V, Todoerti K, Neri A.
    Curr Treat Options Oncol; 2016 Apr 01; 17(4):19. PubMed ID: 26995215
    [Abstract] [Full Text] [Related]

  • 5. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
    Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P.
    Expert Rev Hematol; 2016 Nov 01; 9(11):1063-1073. PubMed ID: 27759436
    [Abstract] [Full Text] [Related]

  • 6. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ, Wang FR, Wen L, Chen Y, Chen H, Huang XJ, Lu J.
    Zhonghua Nei Ke Za Zhi; 2020 Oct 01; 59(10):801-806. PubMed ID: 32987483
    [Abstract] [Full Text] [Related]

  • 7. An update on biology, diagnosis and treatment of primary plasma cell leukemia.
    Musto P, Statuto T, Valvano L, Grieco V, Nozza F, Vona G, Bochicchio GB, La Rocca F, D'Auria F.
    Expert Rev Hematol; 2019 Apr 01; 12(4):245-253. PubMed ID: 30905220
    [Abstract] [Full Text] [Related]

  • 8. How I treat plasma cell leukemia.
    van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG.
    Blood; 2012 Sep 20; 120(12):2376-89. PubMed ID: 22837533
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H, Zhou H, Zhang Z, Geng C, Chen W.
    Turk J Haematol; 2020 May 06; 37(2):91-97. PubMed ID: 31769277
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.
    J Clin Oncol; 2016 Jun 20; 34(18):2125-32. PubMed ID: 27114594
    [Abstract] [Full Text] [Related]

  • 11. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
    Katodritou E, Kastritis E, Dalampira D, Delimpasi S, Spanoudakis E, Labropoulou V, Ntanasis-Stathopoulos I, Gkioka AI, Giannakoulas N, Kanellias N, Papadopoulou T, Sevastoudi A, Michalis E, Papathanasiou M, Kotsopoulou M, Sioni A, Triantafyllou T, Daiou A, Papadatou M, Kyrtsonis MC, Pouli A, Kostopoulos I, Verrou E, Dimopoulos MA, Terpos E.
    Am J Hematol; 2023 May 20; 98(5):730-738. PubMed ID: 36869876
    [Abstract] [Full Text] [Related]

  • 12. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, Dimopoulos MA.
    Am J Hematol; 2014 Feb 20; 89(2):145-50. PubMed ID: 24123068
    [Abstract] [Full Text] [Related]

  • 13. Primary plasma cell leukemia in the era of new drugs: has something changed?
    Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omede' P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A.
    Crit Rev Oncol Hematol; 2012 May 20; 82(2):141-9. PubMed ID: 21719304
    [Abstract] [Full Text] [Related]

  • 14. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, Zang M, Sui W, Yi S, Li Z, Hao M, Feng X, Jin F, Zou D, Qi J, Zhao Y, Tai YT, Wang J, Qiu L.
    Ann Hematol; 2015 Feb 20; 94(2):257-64. PubMed ID: 25231928
    [Abstract] [Full Text] [Related]

  • 15. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A, for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori).
    Ann Oncol; 2011 Jul 20; 22(7):1628-1635. PubMed ID: 21252060
    [Abstract] [Full Text] [Related]

  • 16. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
    Peña C, Riva E, Schutz N, Ramírez A, Vásquez J, Del Carpio D, Seehaus C, Ochoa P, Vengoa R, Duarte P, Martínez-Cordero H, Figueredo Y, Ríos RO, Ramírez J, Bove V, Roa M, Russo M, Espinoza M, Rodriguez G, Remaggi G, Enciso ME, Chandía M, Fantl D, Grupo de Estudio Latinoamericano de Mieloma Múltiple (GELAMM).
    Leuk Lymphoma; 2023 Apr 20; 64(4):816-821. PubMed ID: 36695519
    [Abstract] [Full Text] [Related]

  • 17. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
    Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F, Yamamoto G, Handa H, Saitoh T, Nagura E, Shimizu K, Nojima Y, Murakami H.
    Acta Haematol; 2016 Apr 20; 135(2):113-21. PubMed ID: 26505781
    [Abstract] [Full Text] [Related]

  • 18. Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
    Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME, Israeli Multiple Myeloma Study Group.
    Leuk Res; 2018 May 20; 68():9-14. PubMed ID: 29501828
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
    Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA.
    Biol Blood Marrow Transplant; 2013 Aug 20; 19(8):1144-51. PubMed ID: 23416092
    [Abstract] [Full Text] [Related]

  • 20. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
    Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Go RS, Jevremovic D, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI.
    Mayo Clin Proc; 2021 Mar 20; 96(3):677-687. PubMed ID: 33673918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.